JAK2 inhibitors (JAK2-Is) have also been combined with IM, NIL and DAS killing CML cells and restoring TKI-sensitivity in resistant CML cell lines [71–73]. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.